Veracyte Announces Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- S&P 500 subdued as gains in banks offset AI jitters; Dow at one-month high
- Oil heads for weekly gain with focus on Middle East supply
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Vertiv shares fall on analyst downgrades and options bets
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Stocks edge lower as dollar heads for weekly loss
- S&P 500 ends higher as traders shift from AI to healthcare
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
Piper Jaffray Trims PT on Veracyte (VCYT) to $12, Maintains 'Overweight'
August 14, 2015 7:33 AM EDTPiper Jaffray analyst William Quirk reiterated an Overweight rating but trimmed his price target on Veracyte, Inc (NASDAQ: VCYT) to $12.00 (from $13.00) following Q3 results and outook.
Quirk commented, "Veracyte reported a 37.2% yoy revenue increase to $11.9M, above our $11.7M estimate, but below... More
Veracyte (VCYT) Misses Q2 EPS by 4c
August 13, 2015 4:35 PM EDTVeracyte (NASDAQ: VCYT) reported Q2 EPS of ($0.35), $0.04 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $11.9 million versus the consensus estimate of $12.23 million.
Veracyte reaffirmed FY2015 guidance.
"We continue to see strong growth of Afirma across both community-based physicians... More



